Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lobeglitazone - Chong Kun Dang

Drug Profile

Lobeglitazone - Chong Kun Dang

Alternative Names: CKD 396; CKD-501; Duvie; Lobeglitazone sulfate

Latest Information Update: 07 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chong Kun Dang
  • Developer Chong Kun Dang; EQUIS & ZAROO
  • Class Antihyperglycaemics; Pyrimidines; Small molecules; Thiazolidinediones
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 13 Nov 2018 Chong Kun Dang Pharmaceutical completes a phase I drug drug interaction trial in South Korea (NCT03616392)
  • 09 Nov 2018 Chong Kun Dang Pharmaceutical initiates a phase III trial for Type 2 diabetes mellitus (Combination therapy) in South Korea (PO) (NCT03739125)
  • 25 Jul 2018 Chong Kun Dang Pharmaceutical initiates a phase I drug drug interaction trial in South Korea (NCT03616392)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top